Trial Profile
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Ozanimod (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Sponsors Celgene Corporation; Celgene International SARL
- 15 Mar 2024 This trial has been completed in Belgium.
- 25 Oct 2023 This trial has been completed in Austria, according to European Clinical Trials Database record.
- 13 Oct 2023 Planned End Date changed from 27 Dec 2029 to 24 Mar 2031.